Loading
Total declarations
Companies
▲ Purchases (3 ops.)
▼ Sales (0 ops.)
Latest filing published 19 Mar 2026 for Aldeyra Therapeutics, Inc., €6,153.
Filing timeline
BuySaleMichael Alfieri
Insider track record
Disclosed buys
3
Disclosed sells
0
Signal history
Closed purchases
Market purchases
3
Positive at T+90
67%
Median T+90
+8.3%
Based on 3 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Purchases by company
Since each purchase
- +8.3%Entry US$1.81 · Close at T+90 US$1.96
- -71.3%Entry US$5.44 · Close at T+365 US$1.56
- -11.1%Entry US$4.05 · Close at T+365 US$3.60
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Michael Alfieri: trading record in brief
Filings by Michael Alfieri span 2 companies, the busiest being Aldeyra Therapeutics, Inc. and Genocea Biosciences, Inc. Over a trading history stretching from 13 September 2018 to 18 March 2026, the count stands at 3 filings.
The open-market record is one-sided, with 3 purchases worth €22k and not one sale. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Since January 2026: 1 purchase and no sales on the market.
Half of the purchases are above €6,153 and half below. The 3 purchases reviewed show no overlap with other insiders buying the same stock within a month. After 3 purchases with a full 90-day history, the hit rate stands at 67% and the median 90-day move at +8.3%. They describe history only and say nothing certain about the share price ahead.
Most recently, on 19 March 2026, the filings show an open-market purchase worth €6,153 in Aldeyra Therapeutics, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 1 day. The legal deadline for a Form 4 is two business days after the transaction. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Companies and markets linked to Michael Alfieri
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations3 total
5,000 shares@ US$1.4235.2% of flowCommon StockSEC:0001193125-26-116247:0
Canonical exit: 16 Jun 2026 (T+90)
2,500 shares@ US$5.3064.8% of flowCommon StockSEC:0000950170-25-109391:0
Canonical exit: 11 Nov 2025 (T+90)
10,000 shares@ US$0.54100.0% of flowCommon StockSEC:0001457612-18-000082:0
Canonical exit: 12 Dec 2018 (T+90)
3 of 3 declarations
